StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX – Free Report) in a research report sent to investors on Thursday. The brokerage issued a hold rating on the stock.
Brooklyn ImmunoTherapeutics Price Performance
Brooklyn ImmunoTherapeutics stock opened at $0.30 on Thursday. The stock has a market capitalization of $17.65 million, a P/E ratio of -0.13 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 12-month low of $0.17 and a 12-month high of $10.10. The firm’s 50-day moving average is $0.49 and its two-hundred day moving average is $1.16.
Brooklyn ImmunoTherapeutics Company Profile
See Also
- Five stocks we like better than Brooklyn ImmunoTherapeutics
- Bank Stocks – Best Bank Stocks to Invest In
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- What Are Dividend Challengers?
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- What Do S&P 500 Stocks Tell Investors About the Market?
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
